Stoke Therapeutics, Inc. (STOK) Q3 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Audra and I will be your conference operator today. At this time, I would like to welcome everyone to the Stoke Therapeutics interim analysis of STK001 for the treatment of Dravet syndrome. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press the star key followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. At this time, I'd like to turn the conference over to Eric Rojas, Head of Investor Relations. Please go ahead. Thanks, Audra, and good morning. This is Eric Rojas, Head of Investor Relations at Stokes Therapeutics. On today's call, we will discuss results from the interim analysis of the Phase 1-2A clinical studies of our investigational medicine STK001 for the treatment of Gervais syndrome. Our speakers today are Dr. Edward Kay, Stokes CEO, and Dr. Barry Tico, Stokes Chief Medical Officer. As you listen to this call, we recommend that you access the webcast slides in the Investors section on our website. This call is being recorded, and a replay will also be available on the Stoke website later today. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the SEC. These statements, including without limitation those regarding Stoke's Dervet Syndrome Program, are based on management's current intentions beliefs, and assumptions. Actual outcomes and events can differ materially. Except as required by law, we assume no obligation to update any such forward-looking statements after the date of this presentation...